Global Tissue Microarray Market Size study & Forecast, by Procedure (Immunohistochemistry, Fluorescence in situ hybridization (FISH), In Situ Hybridization, Other Procedure Types) By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing,

Global Tissue Microarray Market Size study & Forecast, by Procedure (Immunohistochemistry, Fluorescence in situ hybridization (FISH), In Situ Hybridization, Other Procedure Types) By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing, DNA Microarray, Other Technology Types) By End-User (Pharmaceutical and Biotechnological Companies, Research Organizations) and Regional Analysis, 2023-2030

Global Tissue Microarray Market is valued approximately at USD xx billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.30% over the forecast period 2023-2030. Tissue Microarray is a high-throughput technique used in molecular pathology and research to analyze multiple tissue specimens simultaneously on a single microscope slide. The purpose of a Tissue Microarray is to efficiently investigate molecular and genetic characteristics of a large number of tissue samples in a cost-effective manner. The Tissue Microarray market is expanding because of factors such as growing prevalence of cancer and rising demand for personalized medicine. As a result, the demand of Tissue Microarray has progressively increased in the international market during the forecast period 2023-2030.

Precision medicine and targeted therapies in cancer treatment requires detailed molecular profiling of individual tumors. Tissue Microarray technology allows for the simultaneous examination of multiple tissue samples, aiding in the identification of specific molecular alterations and targets. This information is crucial for tailoring treatment strategies based on the specific genetics of cancer patient. According to the International Agency for Research on Cancer, in 2022, global estimated number of deaths due to cancer accounted 9.96 million and is projected to reached up to 12.9 million by 2030. Another important factor driving the Tissue Microarray market is increasing demand for personalized medicine. As Personalized medicine aims to tailor treatment strategies based on the specific characteristics of individual patients, such as genetic makeup, molecular profiles, and disease subtype. Tissue Microarray technology allows researchers to stratify patient populations by analyzing tissue samples for various molecular markers. This stratification is crucial for identifying subgroups that could respond differently to specific treatments. In addition, as per Statista, the global precision medicine treatment spending accounted USD 32017 million in the year 2022 and projected to reach up to USD 123,887 million by the year 2027. Moreover, government funding towards advancement of tissue microarray and growing number of research and development in drug discovery is anticipated to create a lucrative growth opportunity for the market over the forecast period. However, availability of alternative techniques and high cost associated to microarray techniques is going to impede overall market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Tissue Microarray Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the increase in the spending on research and development and growing prevalence of cancer in the region. Increased R&D funding enables companies to invest in the development of new and improved Tissue Microarray products and platforms. Research investment can lead to the creation of user-friendly and more sophisticated Tissue Microarray systems, addressing the evolving needs of researchers and clinicians. The region’s dominant performance is anticipated to propel the overall demand of Tissue Microarray. Furthermore, Asia Pacific region is expected to emerge as the fastest growing region during the forecast period, owing to factors such as supportive government initiative towards cancer in the region.

Major market player included in this report are:
Novus Biologicals LLC
OriGene Technologies, Inc
ProteoGenex, Inc
PREMIER Biosoft International
BioIVT LLC
Impath, LLC
GeneTex, Inc
LGC Limited
Rockland Immunochemicals Inc
CapitalBio Corporation

Recent Developments in the Market:
 In July 2022, Alliance Pharma has completed the acquisition of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organisation (CRO), from LGC. Ampersand Capital Partners, a worldwide healthcare private equity firm, and KKR & Co. Inc a major global investment firm, are both equal shareholders in the combined entity. This deal broadens the bioanalytical, analytical material testing, and laboratory capabilities of the biopharma and pharmaceutical industries globally, including cell and gene therapy, next-generation biologics, material sciences, and protein characterization.

Global Tissue Microarray Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Procedure, Technology, End-User, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Procedure
Immunohistochemistry
Fluorescence in situ hybridization (FISH)
In Situ Hybridization
Other Procedure Types

By Technology
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing
DNA Microarray
Other Technology Types

By End-User
Pharmaceutical and Biotechnological Companies
Research Organizations

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.